Drawing for FERTIN

USPTO serial 98065183

FERTIN

Reviewed by CopyMark Law Group

Status 732Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
SINGER, MELANIE ALYSSA
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 732: Status 732 means the third six-month extension to file a Statement of Use was granted. You are past the midpoint of available extension time — plan SOU filing carefully.

Need help with FERTIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*

Plus Government fees of $450

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamar Niv Bessinger

Tamar Niv Bessinger FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 W 42ND ST 17TH FLOORNEW YORK, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for smoking cessation; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of insomnia and sleep disorders, and to improve quality and quantity of sleep; pharmaceutical preparations to treat fever; pharmaceutical preparations to treat inflammation; Pharmaceutical preparations for the treatment of arthritis; psychotherapeutic pharmaceutical preparations; pharmaceutical preparations for treatment of cold; Pharmaceutical preparations for treatment of flu; Pharmaceutical preparations for treatment of cough; Pharmaceutical preparations for treatment of sinus; Pharmaceutical preparations for treatment of allergy; Pharmaceutical preparations for treatment of cardiovascular diseases; Pharmaceutical preparations for treatment of neurological disorders; Pharmaceutical preparations for treatment of chronic pain; Pharmaceutical preparations for treatment of gastro-intestinal disorders; vitamins; dietary supplements prepared from fruit extracts; dietary supplements prepared from vegetable extracts; dietary supplements prepared from herbal extracts; dietetic supplements prepared from herbal extracts; dietetic supplements prepared from fruit extracts; dietetic supplements prepared from vegetable extracts; nicotine chewing gum for use as aid to stop smoking; medicated chewing gum; dietetic substances adapted for medical use; herbal extracts for medical purposes; herbal teas for medicinal purposesACTIVE—
040Custom manufacture of pharmaceuticals and nutraceuticals; consultancy regarding the custom manufacture of pharmaceuticals and nutraceuticals; provision of advice, information and consultancy in relation to the aforesaid servicesACTIVE—
042Research and development of technology in the field of smoking cessation preparations; research and development of technology in the field of analgesics; research and development of technology in the field of sleep aid drugs; research and development of technology in the field of anti-pyretic drugs; research and development of technology in the field of anti-inflammatory preparations; research and development of technology in the field of pharmaceutical preparations for the treatment of arthritis; research and development of technology in the field of psychotherapeutic preparations; research and development of technology in the field of pharmaceutical preparations for treatment of cold; research and development of technology in the field of pharmaceutical preparations for treatment of flu; research and development of technology in the field of pharmaceutical preparations for treatment of cough; research and development of technology in the field of pharmaceutical preparations for treatment of sinus; research and development of technology in the field of pharmaceutical preparations for treatment of allergy; research and development of technology in the field of pharmaceutical preparations for treatment of cardiovascular diseases; research and development of technology in the field of pharmaceutical preparations for treatment of neurological disorders; research and development of technology in the field of pharmaceutical preparations for treatment of chronic pain; research and development of technology in the field of pharmaceutical preparations for treatment of gastro-intestinal disorders; design of new products for others; scientific and technological services in the nature of testing of new products for others; medical research services; scientific research services; pharmaceutical products development; formulation of inhaled therapeutics; research and development of inhaled therapeutics; formulation of pharmaceuticals for oral and intra-oral delivery systems; research and development of pharmaceuticals for oral and intra-oral delivery systemsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 4, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 4, 2026EX3GSOU EXTENSION 3 GRANTED—
Aug 4, 2026EXT3SOU EXTENSION 3 FILED—
Aug 4, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 29, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 28, 2026EX2GSOU EXTENSION 2 GRANTED—
Jan 28, 2026EXT2SOU EXTENSION 2 FILED—
Jan 28, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 26, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 25, 2025EX1GSOU EXTENSION 1 GRANTED—
Jul 25, 2025EXT1SOU EXTENSION 1 FILED—
Jul 25, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 4, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 10, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 10, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 4, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 14, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 14, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Nov 14, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 14, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 14, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 6, 2024DOCKASSIGNED TO EXAMINER—
Apr 23, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 23, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Apr 23, 2024CNSLSUSPENSION LETTER WRITTEN—
Dec 15, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 14, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 14, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 14, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 14, 2023DOCKASSIGNED TO EXAMINER—
Aug 1, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 5, 2023PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 3, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance